Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause for concern
- 31 December 1989
- Vol. 34 (6) , 353-356
- https://doi.org/10.1016/0090-4295(89)90440-8
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the UrotheliumNew England Journal of Medicine, 1988
- M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Advanced Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1988
- Neoadjuvant M-Vac (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) Effect on the Primary Bladder LesionJournal of Urology, 1988
- The Fate of the Bladder in Patients with Metastatic Bladder Cancer Treated with Cisplatin, Methotrexate and Vinblastine: A Northern California Oncology Group StudyJournal of Urology, 1985
- Vinblastine and Methotrexate for Advanced Bladder CancerJournal of Urology, 1985
- Learning to Integrate Systemic Chemotherapy into a Treatment Plan for Patients with Advanced Bladder CancerJournal of Urology, 1985
- Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the UrotheliumJournal of Urology, 1985
- Phase II Trial of Sequentially Administered Cisplatin, Cyclophosphamide and Doxorubicin for Urothelial Tract TumorsJournal of Urology, 1983
- The Treatment of Advanced Bladder Cancer with MethotrexateBritish Journal of Urology, 1977
- Clinical trials with adriamycinCancer, 1971